US55279B3015 - Common Stock
MEI PHARMA INC
NASDAQ:MEIP (3/27/2024, 8:27:10 PM)
After market: 3.8 -0.12 (-3.06%)3.92
+0.06 (+1.55%)
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 46 full-time employees. The company went IPO on 2003-12-18. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. The company targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
MEI PHARMA INC
Suite 101, 11975 El Camino Real
San Diego CALIFORNIA 92130
P: 18587926300
CEO: Daniel P. Gold
Employees: 46
Website: https://www.meipharma.com/
MEI Pharma files prospectus for mixed securities shelf offering of up to $100M.
Here you can normally see the latest stock twits on MEIP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: